{"id":"W4387811066","doi":"10.1016/j.annonc.2023.09.2184","title":"1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Reproductive System and Pregnancy","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Chugai Pharmaceutical; Seagen; Genentech; F-star Therapeutics; Sierra Oncology; Pfizer; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sociedad Española de Oncología Médica; BeiGene; Sanofi; Johns Hopkins University; Amgen; Celgene","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Cancer; Oncology; Renal cell carcinoma; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Progressive disease; Pharmacokinetics; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106885,0.0001971845,0.0009938353,0.0001110647,0.000132661,0.000002723235,0.0001683724,0.0002464261,0.00004018391],"category_scores_gemma":[0.0002091566,0.0001354043,0.0001762942,0.0001436911,0.000943344,0.0001041526,0.00008868211,0.0001140177,0.000005681198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001202587,"about_ca_system_score_gemma":0.0001231321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007912017,"about_ca_topic_score_gemma":0.00004539308,"domain_scores_codex":[0.9977959,0.0006360167,0.0007159548,0.000494033,0.00003898136,0.0003190463],"domain_scores_gemma":[0.9967481,0.001833034,0.0006221865,0.0005395687,0.0002210155,0.00003607234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0133785,0.002432461,0.02406271,0.0003995933,0.001106653,0.00001830879,0.002946619,0.00004542642,0.3736947,0.00108331,0.0008875976,0.5799442],"study_design_scores_gemma":[0.005385175,0.04596305,0.6112592,0.0001189382,0.0001716001,0.00006355866,0.001581769,0.00002528565,0.1801027,0.0003895495,0.1547022,0.0002369959],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830688,0.01327324,0.00009463393,0.0009749311,0.0006476944,0.001098814,0.0003813092,0.0000244146,0.000436168],"genre_scores_gemma":[0.9842262,0.01427931,0.0001150612,0.00003289561,0.00006243128,0.00005353149,0.00006385489,0.00001761966,0.001149093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5871965,"threshold_uncertainty_score":0.5521626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1326605395598053,"score_gpt":0.455820497147672,"score_spread":0.3231599575878668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}